Jordan Berlin
Faculty Member
Last active: 5/7/2016

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Chan E, Arlinghaus LR, Cardin DB, Goff L, Berlin JD, Parikh A, Abramson RG, Yankeelov TE, Hiebert S, Merchant N, Bhaskara S, Chakravarthy AB (2016) Radiother Oncol 119(2): 312-8
    › Primary publication · 27106554 (PubMed) · PMC4961249 (PubMed Central)
  2. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler AL, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA (2016) Ann Oncol 27(6): 1180
    › Primary publication · 26945010 (PubMed)
  3. A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study. Cohen SJ, O'Neil BH, Berlin J, Ames P, McKinley M, Horan J, Catalano PM, Davies A, Weekes CD, Leichman L (2016) Cancer Chemother Pharmacol 77(4): 693-701
    › Primary publication · 26886016 (PubMed)
  4. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. Leichman L, Groshen S, O'Neil BH, Messersmith W, Berlin J, Chan E, Leichman CG, Cohen SJ, Cohen D, Lenz HJ, Gold P, Boman B, Fielding A, Locker G, Cason RC, Hamilton SR, Hochster HS (2016) Oncologist 21(2): 172-7
    › Primary publication · 26786262 (PubMed) · PMC4746089 (PubMed Central)
  5. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, Graham M, Sandler MP, Delbeke D, Walker RC (2016) J Nucl Med 57(5): 708-14
    › Primary publication · 26769865 (PubMed)
  6. A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. Goff LW, Cohen RB, Berlin JD, de Braud FG, Lyshchik A, Noberasco C, Bertolini F, Carpentieri M, Stampino CG, Abbattista A, Wang E, Borghaei H (2016) Clin Cancer Res 22(9): 2146-54
    › Primary publication · 26655846 (PubMed)
  7. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE (2014) J Clin Oncol 32(12): 1277-80
    › Primary publication · 24638016 (PubMed)
  8. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Cardin DB, Goff L, Li CI, Shyr Y, Winkler C, DeVore R, Schlabach L, Holloway M, McClanahan P, Meyer K, Grigorieva J, Berlin J, Chan E (2014) Cancer Med 3(3): 572-9
    › Primary publication · 24574334 (PubMed) · PMC4101748 (PubMed Central)
  9. Advanced biliary tract cancers. Goff LW, Berlin JD (2012) Am Soc Clin Oncol Educ Book : 281-2
    › Primary publication · 24451749 (PubMed)
  10. Aflibercept--a decoy VEGF receptor. Ciombor KK, Berlin J (2014) Curr Oncol Rep 16(2): 368
    › Primary publication · 24445500 (PubMed) · PMC5145308 (PubMed Central)
  11. Timing versus duration of adjuvant therapy for pancreatic cancer: all the lessons we need in life are taught to us as children. Chan E, Berlin J (2014) J Clin Oncol 32(6): 487-8
    › Primary publication · 24419124 (PubMed)
  12. Pancreas cancer on the rise: are we up to the challenge? Cardin DB, Berlin JD (2013) J Natl Cancer Inst 105(22): 1675-6
    › Primary publication · 24203986 (PubMed)
  13. Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma. Goyal L, Supko JG, Berlin J, Blaszkowsky LS, Carpenter A, Heuman DM, Hilderbrand SL, Stuart KE, Cotler S, Senzer NN, Chan E, Berg CL, Clark JW, Hezel AF, Ryan DP, Zhu AX (2013) Cancer Chemother Pharmacol 72(6): 1305-14
    › Primary publication · 24121453 (PubMed)
  14. Beyond exon 2--the developing story of RAS mutations in colorectal cancer. Berlin J (2013) N Engl J Med 369(11): 1059-60
    › Primary publication · 24024844 (PubMed)
  15. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing. Cushman-Vokoun AM, Stover DG, Zhao Z, Koehler EA, Berlin JD, Vnencak-Jones CL (2013) Clin Colorectal Cancer 12(3): 168-78
    › Primary publication · 23773459 (PubMed) · PMC4090139 (PubMed Central)
  16. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA (2013) HPB (Oxford) 15(2): 106-15
    › Primary publication · 23297721 (PubMed) · PMC3719916 (PubMed Central)
  17. Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer. Infante JR, Bendell JC, Goff LW, Jones SF, Chan E, Sudo T, Burris HA, Berlin JD (2013) Eur J Cancer 49(6): 1169-75
    › Primary publication · 23294608 (PubMed)
  18. A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer. Chakravarthy AB, Tsai CJ, O'Brien N, Lockhart AC, Chan E, Parikh A, Berlin JD, Merchant N (2012) Gastrointest Cancer Res 5(4): 112-8
    › Primary publication · 23077684 (PubMed) · PMC3433259 (PubMed Central)
  19. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B (2012) Nature 486(7404): 537-40
    › Primary publication · 22722843 (PubMed) · PMC3436069 (PubMed Central)
  20. Neuroendocrine tumors. Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA, National Comprehensive Cancer Networks (2012) J Natl Compr Canc Netw 10(6): 724-64
    › Primary publication · 22679117 (PubMed)
  21. Neuroendocrine carcinoma in an adolescent with hypercortisolemia. Fagan EL, Slone JS, Shoemaker AH, Black J, Berlin J, E Engel M (2012) J Pediatr Hematol Oncol 34(3): e117-9
    › Primary publication · 22441712 (PubMed)
  22. Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE). Polite BN, Sing A, Sargent DJ, Grothey A, Berlin J, Kozloff M, Feng S (2012) Cancer 118(4): 1083-90
    › Primary publication · 21800287 (PubMed)
  23. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Lorusso PM, Jimeno A, Dy G, Adjei A, Berlin J, Leichman L, Low JA, Colburn D, Chang I, Cheeti S, Jin JY, Graham RA (2011) Clin Cancer Res 17(17): 5774-82
    › Primary publication · 21753154 (PubMed)
  24. Current treatment options for pancreatic carcinoma. Castellanos E, Berlin J, Cardin DB (2011) Curr Oncol Rep 13(3): 195-205
    › Primary publication · 21491194 (PubMed)
  25. Treatment of early-stage pancreatic cancer. Castellanos EH, Cardin DB, Berlin JD (2011) Oncology (Williston Park) 25(2): 182-9
    › Primary publication · 21456390 (PubMed)
  26. Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Puzanov I, Lee W, Chen AP, Calcutt MW, Hachey DL, Vermeulen WL, Spanswick VJ, Liao CY, Hartley JA, Berlin JD, Rothenberg ML (2011) Clin Cancer Res 17(11): 3794-802
    › Primary publication · 21346148 (PubMed) · PMC3107910 (PubMed Central)
  27. Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer. Chan E, Lafleur B, Rothenberg ML, Merchant N, Lockhart AC, Trivedi B, Chung CH, Coffey RJ, Berlin JD (2011) Am J Clin Oncol 34(6): 581-6
    › Primary publication · 21217396 (PubMed) · PMC3133812 (PubMed Central)
  28. Pancreatic adenocarcinoma. Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW, Malafa MP, Muscarella P, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA, NCCN Pancreatic Adenocarcinoma (2010) J Natl Compr Canc Netw 8(9): 972-1017
    › Primary publication · 20876541 (PubMed) · PMC3135380 (PubMed Central)
  29. Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. Goff LW, Benson AB, LoRusso PM, Tan AR, Berlin JD, Denis LJ, Benner RJ, Yin D, Rothenberg ML (2012) Invest New Drugs 30(1): 290-8
    › Primary publication · 20857171 (PubMed)
  30. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Kozloff MF, Berlin J, Flynn PJ, Kabbinavar F, Ashby M, Dong W, Sing AP, Grothey A (2010) Oncology 78(5-6): 329-39
    › Primary publication · 20733336 (PubMed)
  31. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Van Cutsem E, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, De Gramont A, Diaz-Rubio E, Ducreux M, Geva R, Glimelius B, Glynne Jones R, Grothey A, Gruenberger T, Haller D, Haustermans K, Labianca R, Lenz HJ, Minsky B, Nordlinger B, Ohtsu A, Pavlidis N, Rougier P, Schmiegel W, Van de Velde C, Schmoll HJ, Sobrero A, Tabernero J (2010) Ann Oncol : vi1-10
    › Primary publication · 20534623 (PubMed)
  32. Protocol for the examination of specimens from patients with carcinoma of the distal extrahepatic bile ducts. Washington MK, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Vauthey JN, Members of the Cancer Committee, College of American Pathologists (2010) Arch Pathol Lab Med 134(4): e8-13
    › Primary publication · 20367298 (PubMed)
  33. Protocol for the examination of specimens from patients with carcinoma of the perihilar bile ducts. Washington MK, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Vauthey JN, Members of the Cancer Committee, College of American Pathologists (2010) Arch Pathol Lab Med 134(4): e19-24
    › Primary publication · 20367295 (PubMed)
  34. Protocol for the examination of specimens from patients with carcinoma of the intrahepatic bile ducts. Washington MK, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Vauthey JN, Members of the Cancer Committee, College of American Pathologists (2010) Arch Pathol Lab Med 134(4): e14-8
    › Primary publication · 20367294 (PubMed)
  35. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Hecht JR, Mitchell E, Neubauer MA, Burris HA, Swanson P, Lopez T, Buchanan G, Reiner M, Gansert J, Berlin J (2010) Clin Cancer Res 16(7): 2205-13
    › Primary publication · 20332321 (PubMed)
  36. Chemotherapy: Gemcitabine remains the standard of care for pancreatic cancer. Berlin J, Benson AB (2010) Nat Rev Clin Oncol 7(3): 135-7
    › Primary publication · 20190797 (PubMed)
  37. Update on adjuvant trials for pancreatic cancer. Backlund DC, Berlin JD, Parikh AA (2010) Surg Oncol Clin N Am 19(2): 391-409
    › Primary publication · 20159521 (PubMed)
  38. Aurora kinase inhibitors--rising stars in cancer therapeutics? Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W (2010) Mol Cancer Ther 9(2): 268-78
    › Primary publication · 20124450 (PubMed) · PMC2820587 (PubMed Central)
  39. Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the stomach. Washington MK, Tang LH, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Members of the Cancer Committee, College of American Pathologists (2010) Arch Pathol Lab Med 134(2): 187-91
    › Primary publication · 20121605 (PubMed)
  40. Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the small intestine and ampulla. Washington MK, Tang LH, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Members of the Cancer Committee, College of American Pathologists (2010) Arch Pathol Lab Med 134(2): 181-6
    › Primary publication · 20121604 (PubMed)
  41. Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the colon and rectum. Washington MK, Tang LH, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Members of the Cancer Committee, College of American Pathologists (2010) Arch Pathol Lab Med 134(2): 176-80
    › Primary publication · 20121603 (PubMed)
  42. Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the appendix. Washington MK, Tang LH, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Members of the Cancer Committee, College of American Pathologists (2010) Arch Pathol Lab Med 134(2): 171-5
    › Primary publication · 20121602 (PubMed)
  43. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J (2009) J Clin Oncol 27(33): 5660-9
    › Primary publication · 19858397 (PubMed)
  44. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Washington MK, Berlin J, Branton P, Burgart LJ, Carter DK, Fitzgibbons PL, Halling K, Frankel W, Jessup J, Kakar S, Minsky B, Nakhleh R, Compton CC, Members of the Cancer Committee, College of American Pathologists (2009) Arch Pathol Lab Med 133(10): 1539-51
    › Primary publication · 19792043 (PubMed) · PMC2901838 (PubMed Central)
  45. Hiccups: underappreciated and underrecognized. Strickland SA, Berlin JD (2009) J Support Oncol 7(4): 128-9
    › Primary publication · 19731576 (PubMed)
  46. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A, Investigators of the BRiTE study (2009) Oncologist 14(9): 862-70
    › Primary publication · 19726453 (PubMed)
  47. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. Clark OH, Benson AB, Berlin JD, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kessinger A, Kulke MH, Kvols L, Salem R, Saltz L, Shah MH, Shibata S, Strosberg JR, Yao JC, NCCN Neuroendocrine Tumors Panel Members (2009) J Natl Compr Canc Netw 7(7): 712-47
    › Primary publication · 19635226 (PubMed)
  48. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB (2009) J Clin Oncol 27(23): 3778-85
    › Primary publication · 19581537 (PubMed) · PMC2727286 (PubMed Central)
  49. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Gruenberger T, Haller D, Haustermans K, Hoff P, Kerr D, Labianca R, Moore M, Nordlinger B, Ohtsu A, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, van de Velde C (2009) Ann Oncol : vii1-vii6
    › Primary publication · 19497945 (PubMed)
  50. Editorial: Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus conference. Berlin J, Hoffman JP, Regine WF (2009) Ann Surg Oncol 16(7): 1757-9
    › Primary publication · 19396493 (PubMed) · PMC2695869 (PubMed Central)
  51. Controversies in the adjuvant treatment of pancreas cancer: a lack of knowledge or simply a lack of will? Chan E, Berlin JD (2007) Gastrointest Cancer Res 1(5): 204-6
    › Primary publication · 19262710 (PubMed) · PMC2632532 (PubMed Central)
  52. Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors. Ricart AD, Berlin JD, Papadopoulos KP, Syed S, Drolet DW, Quaratino-Baker C, Horan J, Chick J, Vermeulen W, Tolcher AW, Rowinsky EK, Rothenberg ML (2008) Clin Cancer Res 14(23): 7947-55
    › Primary publication · 19047127 (PubMed)
  53. A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies. Goff LW, Rothenberg ML, Lockhart AC, Roth BJ, VerMeulen WL, Chan E, Berlin JD (2008) Am J Clin Oncol 31(5): 413-6
    › Primary publication · 18838875 (PubMed)
  54. Past and future of pancreas cancer: are we ready to move forward together? Merchant N, Berlin J (2008) J Clin Oncol 26(21): 3478-80
    › Primary publication · 18640927 (PubMed)
  55. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R, Amado RG (2008) Clin Colorectal Cancer 7(3): 184-90
    › Primary publication · 18621636 (PubMed)
  56. Protocol for the examination of specimens from patients with primary carcinomas of the colon and rectum. Washington MK, Berlin J, Branton PA, Burgart LJ, Carter DK, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Compton CC, Cancer Committee, College of American Pathologists (2008) Arch Pathol Lab Med 132(7): 1182-93
    › Primary publication · 18605770 (PubMed)
  57. Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer. Stover DG, Lockhart AC, Berlin JD, Chan E, Sandler AB, Sosman JA, Middlebrook V, Nicol S, Rothenberg ML (2008) Invest New Drugs 26(4): 339-45
    › Primary publication · 18463792 (PubMed)
  58. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA (2008) N Engl J Med 358(11): 1109-17
    › Primary publication · 18337601 (PubMed) · PMC2361129 (PubMed Central)
  59. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. Small W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, McGinn CJ (2008) J Clin Oncol 26(6): 942-7
    › Primary publication · 18281668 (PubMed)
  60. Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. Berlin JD, Venook A, Bergsland E, Rothenberg M, Lockhart AC, Rosen L (2008) Clin Colorectal Cancer 7(1): 44-7
    › Primary publication · 18279576 (PubMed)
  61. A 17 year-old man with an exon 11 mutation of CD-117 causing a gastrointestinal stromal tumor. Bauer TM, Berlin JD (2008) Cancer Invest 26(2): 182-4
    › Primary publication · 18259950 (PubMed)
  62. A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Chan E, Mulkerin D, Rothenberg M, Holen KD, Lockhart AC, Thomas J, Berlin J (2008) Invest New Drugs 26(3): 241-7
    › Primary publication · 18217204 (PubMed)
  63. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. O'Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, Goldberg RM (2007) J Clin Oncol 25(24): 3644-8
    › Primary publication · 17704414 (PubMed)
  64. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ (2007) Cancer 110(5): 980-8
    › Primary publication · 17671985 (PubMed)
  65. Adjuvant therapy for pancreatic cancer: to treat or not to treat? Berlin JD (2007) Oncology (Williston Park) 21(6): 712-8; discussion 720, 725-6, 730
    › Primary publication · 17564327 (PubMed)
  66. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Berlin J, Posey J, Tchekmedyian S, Hu E, Chan D, Malik I, Yang L, Amado RG, Hecht JR (2007) Clin Colorectal Cancer 6(6): 427-32
    › Primary publication · 17531105 (PubMed)
  67. Ethics in oncology: consulting for the investment industry. Berlin J, Bruinooge SS, Tannock IF (2007) J Clin Oncol 25(4): 444-6
    › Primary publication · 17264341 (PubMed)
  68. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. Kim DW, Blanke CD, Wu H, Shyr Y, Berlin J, Beauchamp RD, Chakravarthy B (2007) Int J Radiat Oncol Biol Phys 67(2): 397-404
    › Primary publication · 17097833 (PubMed)
  69. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Bartlett DL, Berlin J, Lauwers GY, Messersmith WA, Petrelli NJ, Venook AP (2006) Ann Surg Oncol 13(10): 1284-92
    › Primary publication · 16955384 (PubMed)
  70. Adjuvant and neoadjuvant approaches to treat surgically resectable pancreatic cancer. Keedy VL, Berlin J (2006) Curr Treat Options Oncol 7(5): 381-8
    › Primary publication · 16904055 (PubMed)
  71. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Hochster HS, Haller DG, de Gramont A, Berlin JD, Philip PA, Moore MJ, Ajani JA (2006) Cancer 107(4): 676-85
    › Primary publication · 16847885 (PubMed)
  72. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, Lockhart AC, Medina D, Sosman J, Gordon GB, Rothenberg ML (2006) Clin Cancer Res 12(9): 2834-40
    › Primary publication · 16675578 (PubMed)
  73. Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. Lockhart AC, Cropp GF, Berlin JD, Donnelly E, Schumaker RD, Schaaf LJ, Hande KR, Fleischer AC, Hannah AL, Rothenberg ML (2006) Am J Clin Oncol 29(2): 109-15
    › Primary publication · 16601426 (PubMed)
  74. Anti-angiogenic treatment of gastrointestinal malignancies. Salmon JS, Lockhart AC, Berlin J (2005) Cancer Invest 23(8): 712-26
    › Primary publication · 16377590 (PubMed)
  75. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. Rothenberg ML, LaFleur B, Levy DE, Washington MK, Morgan-Meadows SL, Ramanathan RK, Berlin JD, Benson AB, Coffey RJ (2005) J Clin Oncol 23(36): 9265-74
    › Primary publication · 16361624 (PubMed)
  76. Current and future strategies for treating metastatic pancreatic cancer. Berlin JD (2004) Clin Adv Hematol Oncol 2(8): 510-2
    › Primary publication · 16163230 (PubMed)
  77. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H (2005) J Surg Oncol 91(3): 173-80
    › Primary publication · 16118771 (PubMed)
  78. A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. Morgan-Meadows S, Mulkerin D, Berlin JD, Kim K, Bailey H, Saphner T, Jumonville A, Hansen R, Ahuja H, McFarland T, Thomas JP (2005) Oncology 69(2): 130-4
    › Primary publication · 16118509 (PubMed)
  79. A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. Tedesco KL, Berlin J, Rothenberg M, Choy H, Wyman K, Scott Pearson A, Daniel Beauchamp R, Merchant N, Lockhart AC, Shyr Y, Caillouette C, Chakravarthy B (2005) Radiother Oncol 76(1): 54-8
    › Primary publication · 15921772 (PubMed)
  80. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F (2005) J Clin Oncol 23(15): 3502-8
    › Primary publication · 15908660 (PubMed)
  81. Treatment for pancreatic cancer: current therapy and continued progress. Lockhart AC, Rothenberg ML, Berlin JD (2005) Gastroenterology 128(6): 1642-54
    › Primary publication · 15887156 (PubMed)
  82. Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer. Tedesco KL, Berlin J, Blanke CD, Teng M, Choy H, Roberts J, Beauchamp RD, Leach S, Wyman K, Tarpley J, Shyr Y, Caillouette C, Chakravarthy B (2005) Int J Radiat Oncol Biol Phys 61(5): 1364-70
    › Primary publication · 15817338 (PubMed)
  83. The epidermal growth factor receptor as a target for colorectal cancer therapy. Lockhart AC, Lockhart C, Berlin JD (2005) Semin Oncol 32(1): 52-60
    › Primary publication · 15726506 (PubMed)
  84. The epidermal growth factor receptor as a target for gastrointestinal cancer therapy. Tedesco KL, Lockhart AC, Berlin JD (2004) Curr Treat Options Oncol 5(5): 393-403
    › Primary publication · 15341677 (PubMed)
  85. Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group. Shepard RC, Levy DE, Berlin JD, Stuart K, Harris JE, Aviles V, Thomas JP, Benson AB (2004) Oncology 66(4): 303-9
    › Primary publication · 15218298 (PubMed)
  86. Use of percutaneous drainage to treat hepatic abscess after radiofrequency ablation of metastatic pancreatic adenocarcinoma. Thomas KT, Bream PR, Berlin J, Meranze SG, Wright JK, Chari RS (2004) Am Surg 70(6): 496-9
    › Primary publication · 15212401 (PubMed)
  87. A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors. Lockhart AC, Howard M, Hande KR, Roth BJ, Berlin JD, Vreeland F, Campbell A, Fontana E, Fiorentini F, Fowst C, Paty VA, Lankford O, Rothenberg ML (2004) Clin Cancer Res 10(2): 468-75
    › Primary publication · 14760067 (PubMed)
  88. Diagnosis and treatment of cholangiocarcinoma. Anderson CD, Pinson CW, Berlin J, Chari RS (2004) Oncologist 9(1): 43-57
    › Primary publication · 14755014 (PubMed)
  89. Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific? Rothenberg ML, Berlin JD (2003) J Clin Oncol 21(20): 3716-7
    › Primary publication · 12963700 (PubMed)
  90. Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. Meadows SM, Mulkerin D, Berlin J, Bailey H, Kolesar J, Warren D, Thomas JP (2002) Int J Gastrointest Cancer 32(2-3): 125-8
    › Primary publication · 12794248 (PubMed)
  91. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG (2003) J Clin Oncol 21(11): 2059-69
    › Primary publication · 12775730 (PubMed)
  92. Chemotherapeutic advances in pancreatic cancer. Berlin JD, Rothenberg ML (2003) Curr Oncol Rep 5(3): 219-26
    › Primary publication · 12667419 (PubMed)
  93. Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy. Morgan-Meadows S, Thomas JP, Mulkerin D, Berlin JD, Bailey H, Binger K, Volkman J, Alberti D, Feierabend C, Marrocha R, Arzoomanian RZ, Wilding G (2002) Invest New Drugs 20(4): 377-82
    › Primary publication · 12448654 (PubMed)
  94. Targeting vascular endothelial growth factor in colorectal cancer. Berlin JD (2002) Oncology (Williston Park) 16(8 Suppl 7): 13-5
    › Primary publication · 12199627 (PubMed)
  95. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB (2002) J Clin Oncol 20(15): 3270-5
    › Primary publication · 12149301 (PubMed)
  96. Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy. Liu G, Berlin J, Tutsch KD, Van Ummersen L, Dresen A, Marnocha R, Arzomanian R, Alberti D, Feierabend C, Binger K, Wilding G (2002) Clin Cancer Res 8(3): 706-11
    › Primary publication · 11895899 (PubMed)
  97. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Blanke CD, Haller DG, Benson AB, Rothenberg ML, Berlin J, Mori M, Hsieh YC, Miller LL (2001) Ann Oncol 12(11): 1575-80
    › Primary publication · 11822757 (PubMed)
  98. Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food. Berlin J, Tutsch KD, Arzoomanian RZ, Alberti D, Binger K, Feierabend C, Dresen A, Marnocha R, Pluda J, Wilding G (2002) Clin Cancer Res 8(1): 86-94
    › Primary publication · 11801543 (PubMed)
  99. Chemotherapy for resectable and advanced pancreatic cancer. Berlin JD, Rothenberg M (2001) Oncology (Williston Park) 15(10): 1241-9, 1254; discussion 1254-64
    › Primary publication · 11702956 (PubMed)
  100. New directions in the treatment of advanced colorectal cancer. Berlin J (2001) Oncology (Williston Park) 15(3 Suppl 5): 27-30
    › Primary publication · 11301837 (PubMed)
  101. Second-line therapy in colorectal cancer. Berlin J (2000) Oncology (Williston Park) 14(12 Suppl 11): 21-6
    › Primary publication · 11204658 (PubMed)
  102. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson AB (2000) J Clin Oncol 18(19): 3384-9
    › Primary publication · 11013279 (PubMed)
  103. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296). Berlin JD, Adak S, Vaughn DJ, Flinker D, Blaszkowsky L, Harris JE, Benson IIIAB (2000) Oncology 58(3): 215-8
    › Primary publication · 10765123 (PubMed)
  104. A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors. Berlin JD, Alberti DB, Arzoomanian RZ, Feierabend CA, Simon KJ, Binger KA, Marnocha RM, Wilding G (1998) Invest New Drugs 16(4): 325-30
    › Primary publication · 10426665 (PubMed)
  105. Phase II evaluation of treatment of complete resection of hepatic metastases from colorectal cancer and adjuvant hepatic arterial infusion of floxuridine: an Eastern Cooperative Oncology Group Study (PB083). Berlin J, Merrick HW, Smith TJ, Lerner H (1999) Am J Clin Oncol 22(3): 291-3
    › Primary publication · 10362339 (PubMed)
  106. 5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889). Berlin JD, Propert KJ, Trump D, Wilding G, Hudes G, Glick J, Burch P, Keller A, Loehrer P (1998) Am J Clin Oncol 21(2): 171-6
    › Primary publication · 9537206 (PubMed)
  107. Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy. Berlin J, Stewart JA, Storer B, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Wilding G (1998) J Clin Oncol 16(3): 1142-9
    › Primary publication · 9508201 (PubMed)
  108. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. Schiller JH, Storer B, Berlin J, Wittenkeller J, Larson M, Pharo L, Larson M, Berry W (1996) J Clin Oncol 14(6): 1913-21
    › Primary publication · 8656260 (PubMed)
  109. A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma. Berlin J, King AC, Tutsch K, Findlay JW, Kohler P, Collier M, Clendeninn NJ, Wilding G (1994) Invest New Drugs 12(2): 137-41
    › Primary publication · 7860231 (PubMed)